1. Nanostructured candesartan or a pharmaceutically acceptable ester thereof having an average particle size of less than about 500 nm, preferably from 500 nm to 50 nm. The nanostructured candesartan ester according to claim 1, wherein the pharmaceutically acceptable candesartan ester is candesartan cilexetil. A stable nanostructured composition comprising: (a) nanostructured candesartan or a pharmaceutically acceptable ester thereof having an average particle size of less than about 500 nm, preferably from 500 nm to 50 nm； and (b) at least one stabilizer, where the composition is optionally prepared in a continuous flow reactor, preferably in a continuous flow reactor based on micro-jet technology. The stable nanostructured composition according to claim 3, wherein the pharmaceutically acceptable candesartan ester is candesartan cilexetil and the stabilizer (s) are selected from the group of hydroxypropyl methylcellulose, cellulose acetate phthalate, hydroxypropyl cellulose, polyvinylpyrrolidone, sodium lauric acid, sodium tartaric acid, alcohol, sorbitol esters, polyoxyethylene derivatives of castor oil, poly (meth) acrylate-based polymers and copolymers； a copolymer of ethenyl ester of acetic acid and 1-ethenyl-2-pyrrolidinone (PVP / VA copolymers), sodium dodecylbenzenesulfonate, tocopheryl polyethylene glycol succinates, polyethoxylated castor oils and their derivatives, polyoxyethylene sorbitol esters and fatty acids； polyethylene glycols； polyoxyethylene stearates； methyl cellulose, hydroxyethyl cellulose1. Наноструктурированный кандесартан или его фармацевтически приемлемый эфир, имеющий средний размер частиц менее чем примерно 500 нм, предпочтительно от 500 нм до 50 нм.2. Наноструктурированный эфир кандесартана по п.1, где фармацевтически приемлемый эфир кандесартана представляет собой кандесартан цилексетил.3. Стабильная наноструктурированная композиция, содержащая:(а) наноструктурированный кандесартан или его фармацевтически приемлемый эфир, имеющий средн
